Before the Great Debate: Next step for Lupus Nephritis? #ACR21 @Rheumnow

#ACR21 Great Debate: Voclosporin vs Tacro? ⭐️Voclosporin has carbon bond extension, changing how voclosporin binds to calcineurin. ⭐️Consistent dose-response prevents need for drug monitoring ⭐️Increases potency and results in improved metabolic profile @Rheumnow https://t.co/cY93st7754

Dr. Rovin at #ACR21 Great Debate: ▶️ Disagrees with Dr. Petri that GFR changes are caused by hemodynamics and is temporary, and non-nephrotoxic ▶️ Voclosporin + MMF is safe @Rheumnow https://t.co/TxDyprnZ5u

Personalize decision points in belimumab vs voclosporin @jhrheumatology Dr. Petri ▶️ What is the outcome you are most interested in? GFR? ▶️ Is there extra-renal lupus ▶️ Infection risk ⭐️Ultimately, need biomarkers to know who will respond the best @Rheumnow #ACR21 Great Debate

Enjoyed the @Rheumnow daily panel - #ACR21 day 3 is in the books! https://t.co/Wp48PHRCHn

VEXAS plenary abst#1426 #ACR21 83 patients 🎙️vast majority mutations in p.MET41 Worse mortality when:- ▶️valine mutations on p.MET41 ▶️ear chondritis ▶️being transfusion dependent https://t.co/qnA2lPn5yR

Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain intensity was associated with working life impairment, spinal stiffness, education, gender, depression, anxiety and sleep @RheumNow, #ACR21 and Abst#0360 https://t.co/xEVI4L0Chw

• Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from…

There remains a need to increase knowledge and awareness of #axialspondyloarthritis in this US study of nearly 200 primary care physicians, less than half of the time were IBP symptoms, psoriasis, HLA-B27, CRP or MRI checked @RheumNow, #ACR21 Abst#0370 https://t.co/6Uyy45OEYZ

• Awareness and Attitudes Regarding Axial Spondyloarthritis Among Primary Care Pr…

Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2

Abst0357 #acr2021 @rheumnow Irish registry concludes higher level of unemployment in axSpA pts associated w/high disease activity, poor quality of life & worse spinal mobility https://t.co/GsGPLOoWsk

Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss11.4%. ⬇️ breastfeeding rate at 33.7% https://t.co/plF8fykCKT

Abst0909 #ACR21 @RheumNow #acrbest real life study pinpoints higher disease burden, severity of depressed mood & higher Mean ASAS-HI in F pts w/AS. secukinumab improved disease activity, global functioning and severity of depressive mood in AS patients in both men and women https://t.co/fQycXY1aed

Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy. Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions. What would you choose? #ACR21 #ACRBest @RheumNow https://t.co/FywUp3zCj2

Differences in secukinumab pain response in AxSpA pts based on HLA-B27 sub-types. Homozygous group = more uveitis, arthritis, enthesitis, male Abs#917 #ACR21 @RheumNow https://t.co/3TL9PdS4xx https://t.co/QQ0Tdye1Z9

• Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomi…

EDUCATE! 📣EMPOWER!📣 Prof FMiller shares adaptive measures against predicted impacts of #climate change on rheumatic diseases. 📍We all have a role to play in this. @RheumNow #ACR21 #MedTwitter #RheumTwitter https://t.co/asJcnm104k